Vermillion Lowers Price Target on Public Offering

Feb 14, 2011

NEW YORK (GenomeWeb News) – Vermillion lowered the target of its follow-on offering of stock on Friday after the close of the market.

In a document filed with the US Securities and Exchange Commission, the Austin, Texas-based molecular diagnostics firm said it will register 4.6 million shares of its common stock at $6.49 per share, raising a maximum of almost $29.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

O Canad[ian Science]!

As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.

Brexit Woes Affecting Science Funding

BBC News says the uncertainty over Brexit is affecting science funding in the UK.

"Gayness" App Raises Ire Among Scientists

A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.

Nature Papers Examine the Use of Human and Great Ape Cerebral Organoids, and More

In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.

Featured White Papers

BlueBee Data Security & Compliance

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Oct

21

Featured Webinar

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Genomics is a key element in the potential of precision medicine to transform oncology.

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Menu